Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
KP.2.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LK.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.7.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.25 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.25.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.25.3 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.100 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.44 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LD.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KW.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.15.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LF.3.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDK.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.4.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JQ.2.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.23.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DY.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LJ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LE.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MD.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LE.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDQNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.285NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.582NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.580NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.306NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.280NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.329NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.396NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.595.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.311NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.369NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.367NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.595NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.240NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LR.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KR.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LQ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDK.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.4.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used